Society and Health Research Center, Universidad Mayor, Chile; School of Public Health, Universidad Mayor, Chile; Department of Population Health, New York University, United States.
Society and Health Research Center, Universidad Mayor, Chile.
Drug Alcohol Depend. 2021 Jan 1;218:108405. doi: 10.1016/j.drugalcdep.2020.108405. Epub 2020 Nov 12.
In 2016, California updated its prescription drug monitoring program (PDMP), adding two key features: automated proactive reports to prescribers and mandatory registration for prescribers and pharmacists. The effects of these changes on prescribing patterns have not yet been examined. We aimed to evaluate the joint effect of these two PDMP features on county-level prescribing practices in California.
Using county-level quarterly data from 2012 to 2017, we estimated the absolute change associated with the implementation of these two PDMP features in seven prescribing indicators in California versus a control group comprising counties in Florida and Washington: opioid prescription rate per 1000 residents; patients' mean daily opioid dosage in milligrams of morphine equivalents[MME]; prescribers' mean daily MME prescribed; prescribers' mean number of opioid prescriptions per day; percentage of patients getting >90 MME/day; percentage of days with overlapping prescriptions for opioids and benzodiazepines; multiple opioid provider episodes per 100,000 residents.
Proactive reports and mandatory registration were associated with a 7.7 MME decrease in patients' mean daily opioid dose (95 %CI: -11.4, -2.9); a 1.8 decrease in the percentage of patients prescribed high-dose opioids (95 %CI: -2.3, -0.9); and a 6.3 MME decrease in prescribers' mean daily dose prescribed (95 %CI: -10.0, -1.3).
California's implementation of these two PDMP features was associated with decreases in the total quantity of opioid MMEs prescribed, and indicators of patients prescribed high-dose opioids compared to states that had PDMP's without these features. Rates of opioid prescribing and other high-risk prescribing patterns remained unchanged.
2016 年,加利福尼亚州更新了其处方药物监测计划(PDMP),增加了两个关键功能:向开处方者自动提供主动报告,以及对开处方者和药剂师进行强制性注册。这些变化对处方模式的影响尚未得到检验。我们旨在评估这些 PDMP 功能的两个特点对加利福尼亚州县级处方实践的联合影响。
使用 2012 年至 2017 年的县级季度数据,我们估计了在加利福尼亚州相对于佛罗里达州和华盛顿州的对照组的七个处方指标中实施这两个 PDMP 特征所带来的绝对变化:每千名居民的阿片类药物处方率;患者的平均每日阿片类药物剂量(以毫克等效吗啡剂量[MME]表示);开处方者的平均每日 MME 处方量;开处方者的平均每日阿片类药物处方数;每天获得>90 MME 的患者比例;阿片类药物和苯二氮䓬类药物重叠处方的天数比例;每 10 万居民的多个阿片类药物提供者事件。
主动报告和强制性注册与患者平均每日阿片类药物剂量降低 7.7 MME 相关(95 %CI:-11.4,-2.9);高剂量阿片类药物处方患者比例降低 1.8 (95 %CI:-2.3,-0.9);开处方者平均每日处方剂量降低 6.3 MME(95 %CI:-10.0,-1.3)。
与没有这些功能的州相比,加利福尼亚州实施这两个 PDMP 功能与开处方的阿片类药物 MME 总量减少以及高剂量阿片类药物处方患者的指标相关。阿片类药物和其他高风险处方模式的开具率保持不变。